Patents Examined by Kimberly Ballard
  • Chemical reprogramming of human glial cells into neurons with small molecule cocktail
    Patent number: 9885015
    Abstract: Provided are compositions, articles and methods that relate to promoting neurogenesis or neuroregeneration in mammalian nervous system. Embodiments relate to use of groups of compounds that contain Crizotinib (Cri), Flurbiprofen, Lithium Chloride (Li), Vitamin C (VC), Ceritinib (Cer) or Pirfenidone (PFD). In certain implementations glial cells are converted into functional neurons.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: February 6, 2018
    Assignee: The Penn State Research Foundation
    Inventors: Gong Chen, Lei Zhang, Jiuchao Yin, Ningxin Ma
  • Antibody formulations and methods for treating AL amyloidosis
    Patent number: 9884020
    Abstract: Antibody formulations and methods useful for prophylaxis or treatment of amyloidosis, including AA amyloidosis and AL amyloidosis.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: February 6, 2018
    Assignee: PROTHENA THERAPEUTICS LIMITED
    Inventors: Patrick Garidel, Isaac Craig Henderson, Pamela Klein
  • Nucleic acid molecules encoding for BACE1 antibodies
    Patent number: 9879094
    Abstract: The invention provides antibodies to specific neural proteins and methods of using the same.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: January 30, 2018
    Assignee: Genentech, Inc.
    Inventors: Jasvinder Atwal, Yongmei Chen, Cecilia Pui Chi Chiu, Robert A. Lazarus, Weiru Wang, Ryan J. Watts, Yan Wu, Yingnan Zhang
  • Anti-semaphorin 3A antibody and treatment of Alzheimer's disease and inflammatory immune diseases using same
    Patent number: 9879075
    Abstract: The present invention mainly addresses the problem of providing an antibody against semaphorin 3A protein, said antibody enabling effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome. An anti-Sema 3A antibody comprising CDRs having specific amino acid sequences (SEQ ID NOS: 1-6, 60-62, 64-66, 68-70, 72-74, 76-78, 80-82, 84-86 and 88-90) enables effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome and, therefore, remarkably ameliorates symptoms associated with such a disease.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: January 30, 2018
    Assignee: Yokohama City University and Chiome Bioscience Inc.
    Inventors: Yoshio Goshima, Fumio Nakamura, Naoya Yamashita, Hidetaka Seo, Shuichi Hashimoto, Koji Murakami, Naoki Takahashi, Yukie Sasakura
  • Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
    Patent number: 9879064
    Abstract: The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: January 30, 2018
    Assignee: Horizon Orphan LLC
    Inventors: Todd C. Zankel, Christopher M. Starr
  • TRH binding site in human CNS
    Patent number: 9873717
    Abstract: The invention relates to a novel thyrotropin releasing hormone (TRH) receptor subtype in human central nervous system (CNS) that is pharmacologically distinct from the TRH receptor subtype in human pituitary. The invention provides a means to understand how the central actions of TRH are mediated and to isolate and characterize the novel receptor, as well as methods applicable to research and development of diagnostic and therapeutic applications in human CNS disorders.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: January 23, 2018
    Assignee: THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN
    Inventor: Julie Kelly
  • IL-33 and treatment of neurodegenerative diseases
    Patent number: 9867867
    Abstract: The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to therapies of neurodegenerative diseases. More specifically, the present invention relates to interleukin-33 (IL-33), a fragment thereof, a polynucleotide encoding IL-33 or a fragment thereof for use in treatment or prevention of a neurodegenerative disease involving inflammation in a subject and to a method of treating or preventing a neurodegenerative disease involving neuroinflammation in a subject. Still, the present invention relates to IL-33, a fragment thereof, a polynucleotide encoding IL-33 or a fragment thereof for use in improving or restoring neuronal function or endogenous neuronal repair mechanisms, or enhancing endogenous neurogenesis, oligodendrogenesis or neuronal differentiation in a subject.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: January 16, 2018
    Assignee: MAGIC EPOCH HOLDINGS LIMITED
    Inventors: Jari Koistinaho, Tarja Malm, Eveliina Pollari, Katja Kanninen
  • Human stem cell-derived neural precursors for treatment of autoimmune diseases of the central nervous system
    Patent number: 9862925
    Abstract: The present invention concerns the use of a population of cells comprising: (a) neural precursor cells committed to an oligodendroglial fate; (b) uncommitted neural precursor cells (c) differentiated oligodendrocytes; or (d) a combination of any one of (a) to (c) for the treatment of CNS autoimmune diseases, or for the preparation of a pharmaceutical composition for treating CNS autoimmune diseases, the population of cells being derived from human pluripotent stem cells. The invention also provides methods for obtaining such populations of cells, namely, neural precursor cells committed to an oligodendroglial fate as well as differentiated oligodendrocytes which then can be used in the treatment of CNS autoimmune diseases. A preferred autoimmune disease in the context of the present invention is multiple sclerosis where the population of cells is administered to the CNS for local treatment of the disease.
    Type: Grant
    Filed: October 29, 2008
    Date of Patent: January 9, 2018
    Assignee: Hadasit Medical Research Services & Development Limited
    Inventors: Michal Aharonowiz, Ofira Einstein, Benjamin Reubinoff, Tamir Ben-Hur
  • Composition and method for preventing or treating a tauopathy
    Patent number: 9862761
    Abstract: The present invention is a composition and method for the prevention and treatment of a tauopathy. The composition of the invention includes N-terminal amino acid residues of the tau protein, which have been identified as being involved in toxic activation of a PP1/GSK3 signaling cascade and inhibition of fast axonal transport in human tauopathies.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: January 9, 2018
    Assignees: The Board of Trustes of the University of Illinois, Northwestern University
    Inventors: Scott Thomas Brady, Lester I. Binder, Gerardo Andres Morfini, Nicholas M. Kanaan, Nichole E. LaPointe
  • Single domain antibodies against SOD1 and their use in medicine
    Patent number: 9862777
    Abstract: The present application relates to the field of single-domain antibodies (also called nanobodies), more particularly single-domain antibodies against SOD1 protein isoforms. It also relates to the use of these nanobodies in medicine. Accordingly, methods to treat a disease using these nanobodies are provided herein. The single-domain antibodies are particularly envisaged for treatment of ALS.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: January 9, 2018
    Assignees: VIB VZW, LIFE SCIENCES RESEARCH PARTNERS VZW, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D
    Inventors: Wim Robberecht, Frederic Rousseau, Joost Schymkowitz
  • Compositions and methods for identifying agents for treating apoE-related diseases
    Patent number: 9835633
    Abstract: The present disclosure provides methods of identifying a candidate agent for treating an apoE-associated neurodegenerative disorder. The methods involve contacting a PCSK1 or a PCSK2 polypeptide with an apolipoprotein E polypeptide in the presence of a test agent.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: December 5, 2017
    Assignee: The J. David Gladstone Institutes
    Inventors: Yadong Huang, Qin Xu
  • Antibodies to amyloid beta
    Patent number: 9834598
    Abstract: Antibody for human amyloid beta. Antibody selectively binds human amyloid beta 42 peptide over human amyloid beta 40 peptide. Antibodies specific for amyloid beta 42 as therapeutic agents for binding amyloid beta 42 peptide and treating conditions associated with amyloidosis, such as Alzheimer's disease.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: December 5, 2017
    Assignee: MedImmune Limited
    Inventors: Maria Groves, Suzanne Gustavsson, Kina Höglund, Chris Lloyd, Adrian Nickson, Camilla Niva, Sylvia Simon, David Lowne, Fraser Welsh, Per-Ola Freskgärd
  • Methods for the treatment of central nervous system (CNS) disorders and mood disorders
    Patent number: 9821023
    Abstract: Methods of treating a central nervous system (CNS) disorder or mood disorder in a subject in need of such treatment are described. A therapeutically effective amount of a composition comprising a melanocortin 5 receptor (MC5R) peptide ligand in a pharmaceutically acceptable carrier is administered to the subject. The MC5R peptide ligand is a selective MC5R antagonist, in which administration thereof to the subject can treat the CNS disorder or mood disorder with clinical improvement observed in a relatively short time.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: November 21, 2017
    Assignee: THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
    Inventors: Victor J. Hruby, Minying Cai
  • Methods for the treatment of depression and anxiety
    Patent number: 9814755
    Abstract: Methods of treating a depressive disorder or an anxiety disorder in a subject in need of such treatment are described. A therapeutically effective amount of a composition comprising Ac-Nle4-c[Asp5-His6-(NMe)D-Nal(2?)7-Arg8-Trp9-(NMe)Lys10]-NH2 (PEPTIDE 9), in a pharmaceutically acceptable carrier is administered to the subject. PEPTIDE 9 is a selective MC5R antagonist, in which administration thereof to the subject can treat the depressive or generalized anxiety disorder with clinical improvement observed in a relatively short time.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: November 14, 2017
    Assignee: THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
    Inventors: Victor J. Hruby, Minying Cai, Horst Kessler
  • Neural proteins as biomarkers for nervous system injury and other neural disorders
    Patent number: 9810698
    Abstract: The present invention identifies biomarkers that are diagnostic of nerve cell injury and/or neuronal disorders. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of nerve injury, the cell(s) involved in the injury, and the subcellular localization of the injury.
    Type: Grant
    Filed: November 1, 2016
    Date of Patent: November 7, 2017
    Assignees: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED, BANYAN BIOMARKERS, INC.
    Inventors: Kevin Ka-Wang Wang, Monika Oli, Ming-Cheng Liu
  • Method of pre-treating patients for stroke comprising administering metal chelators to the upper one-third of the nasal cavity
    Patent number: 9801835
    Abstract: Methods for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of stoke, including associated cognitive, behavioral and physical impairments. Initially, a patient at risk for stroke is identified. Effective amounts of therapeutic agents are administered to the upper third of the at-risk patient's nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of a therapeutic agent is the iron chelator deferoxamine (DFO).
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: October 31, 2017
    Assignee: HealthPartners Research Foundation
    Inventors: William H. Frey, II, Samuel Scott Panter, Leah Ranae Bresin Hanson
  • Cell into which protein, which can serve as polymerization nucleus of protein polymer, or polymer thereof is introduced, and method for production of the cell
    Patent number: 9802992
    Abstract: The present invention has the object of providing a cell into which a protein, which can serve as a polymerization nucleus of a protein polymer, or polymer thereof is introduced, and a method for producing the cell. The invention relates to a cell into which a protein, which can serve as a polymerization nucleus of a protein polymer, or a polymer thereof is introduced, a method for producing the cell, and a method of screening for a compound inhibiting an intracellular accumulation of a protein containing fibril structures, wherein the method comprises bringing a candidate substance into contact with the cell.
    Type: Grant
    Filed: December 6, 2006
    Date of Patent: October 31, 2017
    Assignee: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE
    Inventors: Takashi Nonaka, Sayuri Watanabe, Masami Masuda, Masato Hasegawa
  • Biomarker for parkinson's disease and use thereof
    Patent number: 9804174
    Abstract: A antibody has as a target molecule a ubiquitin protein comprising a phosphorylated serine residue at position 65. In addition, a method is provided for specifically detecting Parkinson's disease at an early stage, in which a target molecule is a ubiquitin protein comprising a phosphorylated serine residue at position 65, a pharmaceutical composition for definitively treating or preventing Parkinson's disease, and a method for screening for the pharmaceutical composition.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: October 31, 2017
    Assignee: Tokyo Metropolitan Institute of Medical Science
    Inventors: Noriyuki Matsuda, Fumika Koyano, Kei Okatsu, Etsu Go, Mayumi Kimura, Yasushi Saeki
  • Alzheimer's disease-specific alterations of the ERK1/ERK2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (ADSMB)
    Patent number: 9797913
    Abstract: The present invention relates to methods of diagnosing Alzheimer's Disease as well as to methods of confirming the presence or absence of Alzheimer's Disease in a subject. The present invention is also directed to methods of identifying a lead compound useful for the treatment of Alzheimer's Disease by contacting non-Alzheimers cells with an amyloid beta peptide, stimulating the cells with a protein kinase C activator, contacting the cells with a test compound, and determining the value of an Alzheimer's Disease-specific molecular biomarker. The present invention is also directed to methods of diagnosing Alzheimer's Disease in a subject by detecting alterations in the ratio of specific phosphorylated MAP kinase proteins in cells after stimulation with a protein kinase C activator.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: October 24, 2017
    Assignee: Blanchette Rockefeller Neuroscienses Inc.
    Inventors: Tapan Kumar Khan, Daniel L. Alkon
  • Method for inducing astrocytes
    Patent number: 9796959
    Abstract: The present invention provides a method for producing astrocytes from neural progenitor cells, the method comprising: (1) culturing neural progenitor cells in a culture medium comprising a neurotrophic factor; (2) dissociating the cells obtained in the step (1); and (3) subjecting the cells obtained in the step (2) to adherent culture in a culture medium comprising a neurotrophic factor using an uncoated culture vessel.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: October 24, 2017
    Assignee: KYOTO UNIVERSITY
    Inventors: Haruhisa Inoue, Takayuki Kondo